- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate 230615-70-0
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Nuclear magnetic resonance imaging agent Gadoxetate Disodium 135326-22-6
【Catalog Number】AP8900
【CAS #】 135326-22-6
【Molecular Formula】C23H28GdN3O11Na2
【Molecular Weight】725.71
English Name :
Gadoxetate Disodium
CAS# :
135326-22-6
产品描述
[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]
|
Alias |
Gadoxetate Disodium |
|
Catalog Number |
AP8900 |
|
CAS # |
135326-22-6 |
|
Molecular Formula |
C23H28GdN3O11Na2 |
|
Molecular Weight |
725.71 |
|
Structural Formula |
|
|
Product Introduction CAS 135326-22-6 |
Disodium acetoate, English name is Gadoxetate Disodium, American Chemical Abstracts Registration Number is cas 135326-22-6 Disodium acetic acid (cas 135326-22-6), a new liver-specific MR contrast agent, can significantly improve the detection rate of intrahepatic lesions by T1-weighted MR, combined with the enhanced initial dynamic T1 that can reflect the characteristics of the blood supply of the lesions Weighted MR performance can significantly improve the accuracy of qualitative diagnosis of intrahepatic lesions. |
扫二维码用手机看
VIWIT 沪ICP备12014533号-2
